| Chapter title |
Anti-viral treatment and cancer control.
|
|---|---|
| Chapter number | 14 |
| Book title |
Viruses and Human Cancer
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2014
|
| DOI | 10.1007/978-3-642-38965-8_14 |
| Pubmed ID | |
| Book ISBNs |
978-3-64-238964-1, 978-3-64-238965-8
|
| Authors |
Shih WL, Fang CT, Chen PJ, Wei-Liang Shih, Chi-Tai Fang, Pei-Jer Chen, Shih, Wei-Liang, Fang, Chi-Tai, Chen, Pei-Jer |
| Abstract |
Hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), and Epstein-Barr virus (EBV) contribute to about 10-15 % global burden of human cancers. Conventional chemotherapy or molecular target therapies have been used to treat virus-associated cancers. However, a more proactive approach would be the use of antiviral treatment to suppress or eliminate viral infections to prevent the occurrence of cancer in the first place. Antiviral treatments against chronic HBV and HCV infections have achieved this goal, with significant reduction in the incidence of hepatocellular carcinoma in treated patients. Antiviral treatments for EBV, Kaposi's sarcoma-associated herpesvirus (KSHV), and human T-cell lymphotropic virus type 1 (HTLV-1) had limited success in treating refractory EBV-associated lymphoma and post-transplant lymphoproliferative disorder, KSHV-associated Kaposi's sarcoma in AIDS patients, and HTLV-1-associated acute, chronic, and smoldering subtypes of adult T-cell lymphoma, respectively. Therapeutic HPV vaccine and RNA-interference-based therapies for treating HPV-associated cervical cancers also showed some encouraging results. Taken together, antiviral therapies have yielded promising results in cancer prevention and treatment. More large-scale studies are necessary to confirm the efficacy of antiviral therapy. Further investigation for more effective and convenient antiviral regimens warrants more attention. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| Canada | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Scientists | 1 | 20% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| United States | 1 | 2% |
| Italy | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 50 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 19% |
| Researcher | 8 | 15% |
| Student > Master | 8 | 15% |
| Student > Doctoral Student | 6 | 11% |
| Student > Ph. D. Student | 5 | 9% |
| Other | 10 | 19% |
| Unknown | 7 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 33% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Agricultural and Biological Sciences | 6 | 11% |
| Immunology and Microbiology | 4 | 7% |
| Nursing and Health Professions | 3 | 6% |
| Other | 4 | 7% |
| Unknown | 12 | 22% |